Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Desperate hope: single patient gets custom RNA therapy for returning bone cancer

NCT ID NCT07560709

Disease control Sponsor: University of Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended) This study
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study provided a single patient with recurrent osteosarcoma (a type of bone cancer) access to a personalized treatment made from their own tumor's genetic material. The therapy, called RNA-loaded lipid particles (RNA-LPs), was given intravenously to try to control the cancer. Because it was a one-patient expanded access program, it does not provide broad evidence of safety or effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
personalized RNA-loaded lipid particles (RNA-LPs)
What this could lead to
If it works, this could point toward a treatment for recurrent osteosarcoma that uses the patient's own tumor material to target cancer cells.
What could go wrong
This is a single-patient expanded access protocol, not a formal trial, so results may not apply to others. The treatment is experimental and may not slow disease progression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

15 to 17 years

Sex

Male participants only

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participated in clinical trial * Received pp65 RNA-LPs alone and had pp65/tumor mRNA RNA-LP manufactured * Progressive disease prior to treatment with pp65/tumor mRNA RNA-LP Exclusion Criteria: • Diagnosis of recurrent OSA is not histopathologically confirmed (i.e. pseudoprogression)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recurrent osteosarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recurrent osteosarcoma

Contacts and locations

Locations

  • University of Florida Health

    Gainesville, Florida, 32608, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.